Modular Medical develops patented insulin delivery technologies, aiming to improve access to glycemic control. Its founder, ...

Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...

She was subsequently treated with subcutaneous octreotide via an insulin pump, with a continuous basal rate and additional bolus doses with meals. This led to significant improvements in hypoglycaemia ...

“So the pump can determine based on my blood sugar and carbs, how much insulin to take.” The goal of the multi-year research with UVa and funded by Tandem is to develop a fully automated ...

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented ...

Tandem Diabetes Care, Inc. TNDM has witnessed strong momentum in the past year. Shares of the company have risen 45.7% compared with the industry’s 7.3% growth during the same time frame. The S&P 500 ...

Park Avenue Securities LLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 34.5% in the 4th ...

The variables assessed included glycemic control (glycohemoglobin and blood glucose), total insulin dose, and body weight. Because the interaction effect of these covariates with time (pre- vs.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple ge ...

Means and SDs for glycohemoglobin, blood glucose, insulin dosages, and body weight for CSII and comparison conditions were subjected to meta-analytic procedures. Data regarding pump complications ...